RetinAI Medical AG is a Swiss company founded in early 2017 that specializes in developing innovative solutions in ophthalmology. Their flagship product, RetinAI Discovery®, is a vendor-neutral medical image and data platform designed to harmonize, organize, and aggregate diverse medical imaging data, including DICOM-compliant and proprietary formats. This platform enables healthcare professionals and pharmaceutical companies to manage their data efficiently, gain enhanced insights through automatic AI analysis, and enhance both clinical and research workflows.

The company’s AI models provide automatic and expert-level analysis capabilities such as biomarkers detection, fluid and layer segmentation, and quantification related to retinal pathologies. RetinAI fosters participative research by offering a secured cloud-based environment where collaborators across organizations can access, annotate, and work with datasets with varying permission levels.

RetinAI aims to create a frictionless and open data ecosystem that improves understanding of patients’ diseases and treatment outcomes through advanced insights and knowledge generation. The platform supports various data formats including OCTs, Fundus images, PDFs, and standard image files, consolidating them in a single viewer to avoid the need for multiple viewing tools.

Located at 3 Freiburgstrasse, 3010 Bern, RetinAI Medical AG operates mainly in the digital health sector with a focus on ophthalmology, medical technology, personalized medicine, and health IT. Their business model is enterprise and scale-up focused, striving to enable faster and more accurate decision-making in healthcare to improve patient outcomes globally.